导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.14% | 2122/4773 |
| 近一周 | -1.79% | 2828/5465 |
| 近一月 | -3.22% | 2283/5421 |
| 近一季 | -5.54% | 2106/5231 |
| 近半年 | -0.02% | 1393/4920 |
| 近一年 | 4.59% | 1835/4394 |
| 近两年 | 46.22% | 1626/2954 |
| 近三年 | 27.00% | 1221/2253 |
| 成立以来 | 131.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.37% 3165/4961 |
13.40% 2009/5312 |
- - |
- - |
| 2025 | 20.48% 2117/4813 |
-1.32% 2633/3635 |
2.41% 1584/4076 |
18.22% 2332/4524 |
0.84% 1729/4813 |
| 2024 | 12.40% 1245/3463 |
2.47% 773/2808 |
-1.59% 1080/3014 |
15.14% 1804/3129 |
-3.19% 2285/3463 |
| 2023 | -9.39% 1156/2656 |
4.49% 939/2280 |
-4.03% 1018/2385 |
-3.07% 842/2515 |
-6.78% 1915/2655 |
| 2022 | -18.65% 737/2207 |
-13.53% 776/1919 |
6.66% 643/2016 |
-13.44% 905/2113 |
1.90% 1095/2208 |
| 2021 | 4.69% 567/1822 |
-1.73% 535/1255 |
6.69% 726/1330 |
-2.80% 593/1466 |
2.73% 530/1822 |
| 2020 | 34.89% 433/1250 |
-9.89% 726/1022 |
13.75% 590/1060 |
14.85% 247/1152 |
- - |
| 2019 | 34.73% 391/1092 |
25.43% 462/748 |
0.68% 157/797 |
0.11% 552/844 |
6.57% 591/912 |
| 2018 | -22.35% 236/834 |
- - |
- - |
- - |
-12.09% 399/691 |
| 2017 | 25.31% 115/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.02% 206/605 |
- - |
- - |
- - |
- - |
| 2015 | 0.63% 251/575 |
- - |
- - |
- - |
- - |
| 2014 | 44.94% 108/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.66% 117/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚沪深300指数(LOF)A VS. 长安沪深300非周期A(740101) |